Nanoparticulate systems for combination therapies of lung cancer: A review
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Bray F et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229–26310.3322/caac.21834 ↗
2. Torre LA, Siegel RL, and Jemal A (2016) Lung cancer statistics. Lung cancer and personalized medicine: current knowledge and therapies p. 1–19.10.1007/978-3-319-24223-1_1 ↗
3. Li Q et al (2016) A new hope: the immunotherapy in small cell lung cancer. Neoplasma 63(3):342–35010.4149/302_151001N511 ↗
4. Molina JR et al (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. in Mayo clinic proceedings. Elsevier.10.4065/83.5.584 ↗
5. Travis WD et al (2015) The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10(9):1243–126010.1097/JTO.0000000000000630 ↗
6. Boloker G, Wang C, Zhang J (2018) Updated statistics of lung and bronchus cancer in United States (2018). J Thorac Dis 10(3):115810.21037/jtd.2018.03.15 ↗
7. Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–3010.3322/caac.21442 ↗
8. Memarzia A et al (2023) Therapeutic effects of medicinal plants and their constituents on lung cancer, in vitro, in vivo and clinical evidence. J Cell Mol Med 27(19):2841–286310.1111/jcmm.17936 ↗
9. Lahiri A et al (2023) Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer 22(1):1–3710.1186/s12943-023-01740-y ↗
10. Lehár J et al (2009) Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 27(7):659–66610.1038/nbt.1549 ↗
11. Moradi A et al (2024) Targeted delivery of doxorubicin by SP5-52 peptide conjugated exosome nanoparticles into lung tumor: an in vitro and in vivo study. J Drug Delivery Sci Technol 92:10531310.1016/j.jddst.2023.105313 ↗
12. Wu L, Leng D, Cun D, Foged C, Yang M (2017) Advances in combination therapy of lung cancer: Rationales, delivery technologies and dosage regimens. J Control Release 260:78–91. https://doi.org/10.1016/j.jconrel.2017.05.02310.1016/j.jconrel.2017.05.023 ↗
13. Misra R, Acharya S, Sahoo SK (2010) Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discovery Today 15(19–20):842–85010.1016/j.drudis.2010.08.006 ↗
14. Sahoo SK, Dilnawaz F, Krishnakumar S (2008) Nanotechnology in ocular drug delivery. Drug Discovery Today 13(3–4):144–15110.1016/j.drudis.2007.10.021 ↗
15. Persidis A (1999) Cancer multidrug resistance. Nat Biotechnol 17(1):94–9510.1038/5289 ↗
16. Shirangi A et al (2022) Theranostic silk sericin/SPION nanoparticles for targeted delivery of ROR1 siRNA: synthesis, characterization, diagnosis and anticancer effect on triple- negative breast cancer. Int J Biol Macromol 221:604–61210.1016/j.ijbiomac.2022.09.020 ↗
17. Gurunathan S et al (2018) Nanoparticle-mediated combination therapy: two-in-one approach for cancer. Int J Mol Sci 19(10):326410.3390/ijms19103264 ↗
18. Shirangi A et al (2024) Recent trends in controlled drug delivery based on silk platforms. Silk-Based Biomaterials for Tissue Engineering, Regenerative and Precision Medicine. Elsevier, pp 417–44410.1016/B978-0-323-96017-5.00029-7 ↗
19. Parhi P, Mohanty C, Sahoo SK (2012) Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug Discovery Today 17(17–18):1044–105210.1016/j.drudis.2012.05.010 ↗
20. Delbaldo C et al (2004) Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non–small-cell lung cancer: a meta-analysis. JAMA 292(4):470–48410.1001/jama.292.4.470 ↗
21. Mayer LD, Janoff AS (2007) Optimizing combination chemotherapy by controlling drug ratios. Mol Interventions 7(4):21610.1124/mi.7.4.8 ↗
22. Latimer NR et al (2021) Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multi-stakeholder, international workshop. BMC Health Serv Res 21:1–910.1186/s12913-021-06425-0 ↗
23. Ashton JC (2015) Drug combination studies and their synergy quantification using the Chou-Talalay method. Can Res 75(11):2400–240010.1158/0008-5472.CAN-14-3763 ↗
24. Lammers T, Storm G, and Kiessling F (2010) Nanomedicine formulations for combination therapies. Nano reviews 1.10.3402/nano.v1i0.5705 ↗
25. Mottaghitalab F et al (2015) Silk fibroin nanoparticle as a novel drug delivery system. J Control Release 206:161–17610.1016/j.jconrel.2015.03.020 ↗
26. Farokhi M et al (2016) Importance of dual delivery systems for bone tissue engineering. J Control Release 225:152–16910.1016/j.jconrel.2016.01.033 ↗
27. Doroudian M, Armstrong ME, Donnelly SC (2023) Nano-based therapies for acute and chronic lung diseases. Biotechnology Applied to Inflammatory Diseases: Cellular Mechanisms and Nanomedicine. Springer, pp 271–28610.1007/978-981-19-8342-9_12 ↗
28. Rahimian S et al (2024) Extracellular vesicles and exosomes: novel insights and perspectives on lung cancer from early detection to targeted treatment. Biomedicines 12(1):12310.3390/biomedicines12010123 ↗
29. Doroudian M et al (2021) Smart nanotherapeutics and lung cancer Pharmaceutics 13(11):1972
30. Hanjani NA et al (2022) Emerging role of exosomes as biomarkers in cancer treatment and diagnosis. Crit Rev Oncol Hematol 169:10356510.1016/j.critrevonc.2021.103565 ↗
31. Azhdari MH et al (2022) Molecular insight into the therapeutic effects of stem cell-derived exosomes in respiratory diseases and the potential for pulmonary delivery. Int J Mol Sci 23(11):627310.3390/ijms23116273 ↗
32. Chrastina A, Massey KA, Schnitzer JE (2011) Overcoming in vivo barriers to targeted nanodelivery. Wiley Interdisciplinary Rev Nanomed Nanobiotechnol 3(4):421–43710.1002/wnan.143 ↗
33. Davis ME, Chen Z, Shin DM (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discovery 7(9):771–78210.1038/nrd2614 ↗
34. Zhang X-Q et al (2012) Interactions of nanomaterials and biological systems: implications to personalized nanomedicine. Adv Drug Deliv Rev 64(13):1363–138410.1016/j.addr.2012.08.005 ↗
35. Gadde S (2015) Multi-drug delivery nanocarriers for combination therapy. MedChemComm 6(11):1916–192910.1039/C5MD00365B ↗
36. Cai L et al (2015) Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: a synergistic combination nanotherapy for ovarian cancer treatment. Biomaterials 37:456–46810.1016/j.biomaterials.2014.10.044 ↗
37. Shastri L et al (2015) Synthesis, characterization and bifunctional applications of bidentate silver nanoparticle assisted single drop microextraction as a highly sensitive preconcentrating probe for protein analysis. RSC Adv 5(52):41595–4160310.1039/C5RA04032A ↗
38. Yin T et al (2014) Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound- responsive nanobubbles hetero-assembled from polymeric micelles and liposomes. Biomaterials 35(22):5932–594310.1016/j.biomaterials.2014.03.072 ↗
39. Yang Z-Z et al (2014) Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials (19)35 p. 5226–5239.10.1016/j.biomaterials.2014.03.017 ↗
40. Chen AM et al (2009) Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug resistant cancer cells. Small (Weinheim an der Bergstrasse, Germany) 5(23):267310.1002/smll.200900621 ↗
41. Tian J et al (2017) Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer. Nanomed Nanotechnol Biology Med 13(3):1301–130710.1016/j.nano.2016.11.007 ↗
42. Zhang R et al (2017) Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer. Drug Design, Development and Therapy 2631–2642.10.2147/DDDT.S143047 ↗
43. Crisafulli E et al (2024) Multimodal layer-by-layer nanoparticles: a breakthrough in gene and drug delivery for osteosarcoma. Journal of Materials Chemistry B10.1039/D4TB01541J ↗
44. Zheng C, Li M, Ding J (2021) Challenges and opportunities of nanomedicines in clinical translation. Bio Integration 2(2):57–6010.15212/bioi-2021-0016 ↗
45. Lv S et al (2014) Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer. Biomaterials 35(23):6118–612910.1016/j.biomaterials.2014.04.034 ↗
46. Feng T et al (2014) Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment. Eur J Pharm Biopharm 88(3):1086–109310.1016/j.ejpb.2014.09.012 ↗
47. Wu C et al (2017) Application of a lipid-coated hollow calcium phosphate nanoparticle in synergistic co-delivery of doxorubicin and paclitaxel for the treatment of human lung cancer A549 cells. Int J Nanomed 7979–7992.10.2147/IJN.S140957 ↗
48. Scagliotti GV et al (2012) Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non–small-cell lung cancer. J Clin Oncol 30(2):172–17810.1200/JCO.2010.33.7089 ↗
49. Hanna N et al (2017) Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol.10.1200/JOP.2017.026716 ↗
50. Wakelee HA et al (2017) Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 18(12):1610–162310.1016/S1470-2045(17)30691-5 ↗
51. Huo Q et al (2019) Integrated metalloproteinase, pH and glutathione responsive prodrug- based nanomedicine for efficient target chemotherapy. J Biomed Nanotechnol 15(8):1673–1.68710.1166/jbn.2019.2801 ↗
52. Ling X et al (2018) Glutathione-responsive prodrug nanoparticles for effective drug delivery and cancer therapy. ACS Nano 13(1):357–37010.1021/acsnano.8b06400 ↗
53. Wojtkowiak JW et al (2011) Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm 8(6):2032–203810.1021/mp200292c ↗
54. Wang B et al (2021) Lung cancer chemotherapy using nanoparticles: enhanced target ability of redox-responsive and pH-sensitive cisplatin prodrug and paclitaxel. Biomed Pharmacotherapy 136:11124910.1016/j.biopha.2021.111249 ↗
55. Guo X et al (2018) Advances in redox-responsive drug delivery systems of tumor microenvironment. Journal of Nanobiotechnology 16:1–1010.1186/s12951-018-0398-2 ↗
56. Sharma N et al (2020) Poly-(lactic-co-glycolic) acid nanoparticles for synergistic delivery of epirubicin and paclitaxel to human lung cancer cells. Molecules 25(18):424310.3390/molecules25184243 ↗
57. Khansarizadeh M et al (2016) Identification of possible cytotoxicity mechanism of polyethylenimine by proteomics analysis. Human Experimental Toxicol 4(35):377–38710.1177/0960327115591371 ↗
58. Johnstone TC, Lippard SJ (2013) The effect of ligand lipophilicity on the nanoparticle encapsulation of Pt (IV) prodrugs. Inorg Chem 52(17):9915–992010.1021/ic4010642 ↗
59. Xiao H et al (2012) A prodrug strategy to deliver cisplatin (IV) and paclitaxel in nanomicelles to improve efficacy and tolerance. Biomaterials 33(27):6507–651910.1016/j.biomaterials.2012.05.049 ↗
60. Zhang M et al (2021) Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models. Acta Biomater 124:327–33510.1016/j.actbio.2021.02.001 ↗
61. Zhang Q et al (2019) Cetuximab and doxorubicin loaded dextran-coated Fe3O4 magnetic nanoparticles as novel targeted nanocarriers for non-small cell lung cancer. J Magn Magn Mater 481:122–12810.1016/j.jmmm.2019.01.021 ↗
62. Xu C et al (2019) Pulmonary delivery by exploiting doxorubicin and cisplatin co-loaded nanoparticles for metastatic lung cancer therapy. J Control Release 295:153–16310.1016/j.jconrel.2018.12.013 ↗
63. Nan Y (2019) Lung carcinoma therapy using epidermal growth factor receptor-targeted lipid polymeric nanoparticles co-loaded with cisplatin and doxorubicin. Oncol Rep 42(5):2087–2096
64. Wu R et al (2020) Combination chemotherapy of lung cancer–co-delivery of docetaxel prodrug and cisplatin using aptamer-decorated lipid–polymer hybrid nanoparticles. Drug design, development and therapy 2249–2261.10.2147/DDDT.S246574 ↗
65. Liang Z, Li J, and Zhu B (2020) Lung cancer combination treatment: evaluation of the synergistic effect of cisplatin prodrug, vinorelbine and retinoic acid when co- encapsulated in a multi-layered nano-platform. Drug Design, Development and Therapy 4519–4531.10.2147/DDDT.S251749 ↗
66. Mao K et al (2021) Transferrin-decorated protein-lipid hybrid nanoparticle efficiently delivers cisplatin and docetaxel for targeted lung cancer treatment. Drug Design, Development and Therapy 3475–3486.10.2147/DDDT.S296253 ↗
67. Hu C, Du W (2020) Zinc oxide nanoparticles (ZnO NPs) combined with cisplatin and gemcitabine inhibits tumor activity of NSCLC cells. Aging (albany NY) 12(24):2576710.18632/aging.104187 ↗
68. Al-Mutairi AA, Mayson H, Alkhatib H (2021) Antitumor activities of co-loading gemcitabine and oxaliplatin into oleic acid-based solid lipid nanoparticle against non- small cell lung cancer cells. Biointerface Res Appl Chem 12:49–6010.33263/BRIAC121.049060 ↗
69. Jin Y et al (2020) Synergistic combination chemotherapy of lung cancer: cisplatin and doxorubicin conjugated prodrug loaded, glutathione and pH sensitive nanocarriers. Drug design, development and therapy 5205–5215.10.2147/DDDT.S260253 ↗
70. Rocco D et al (2019) The role of combination chemo-immunotherapy in advanced non- small cell lung cancer. Expert Rev Anticancer Ther 19(7):561–56810.1080/14737140.2019.1631800 ↗
71. Reck M et al (2016) Pembrolizumab versus chemotherapy for PD-L1–positive non–small- cell lung cancer. N Engl J Med 375(19):1823–183310.1056/NEJMoa1606774 ↗
72. Reck M et al (2019) Updated analysis of KEYNOTE-024: pembrolizumab versus platinum- based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater.10.1200/JCO.18.00149 ↗
73. Ogawa JI et al (1993) Immunohistochemical study of glutathione-related enzymes and proliferative antigens in lung cancer. Relation to cisplatin sensitivity Cancer 71(7):2204–2209
74. Privitera G et al (2016) In vitro antiproliferative effect of trastuzumab (Herceptin®) combined with cetuximab (Erbitux®) in a model of human non-small cell lung cancer expressing EGFR and HER2. Clin Exp Med 16:161–16810.1007/s10238-015-0343-8 ↗
75. Marmor MD, Skaria KB, Yarden Y (2004) Signal transduction and oncogenesis by ErbB/HER receptors. International Journal of Radiation Oncology* Biology* Physics 58(3): 903–913.10.1016/j.ijrobp.2003.06.002 ↗
76. Raben D et al (2005) The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 11(2):795–80510.1158/1078-0432.795.11.2 ↗
77. Patel J et al (2018) Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells. J Microencapsul 35(2):204–21710.1080/02652048.2018.1453560 ↗
78. Di Sotto A, Vitalone A, Di Giacomo S (2020) Plant-derived nutraceuticals and immune system modulation: an evidence-based overview. Vaccines 8(3):46810.3390/vaccines8030468 ↗
79. Charoensinphon N et al (2013) 5-D emethyltangeretin inhibits human nonsmall cell lung cancer cell growth by inducing G 2/M cell cycle arrest and apoptosis. Mol Nutr Food Res 57(12):2103–211110.1002/mnfr.201300136 ↗
80. Chen Y-K et al (2015) 5-demethylnobiletin promotes the formation of polymerized tubulin, leads to G2/M phase arrest and induces autophagy via JNK activation in human lung cancer cells. J Nutr Biochem 26(5):484–50410.1016/j.jnutbio.2014.12.003 ↗
81. Mottaghitalab F et al (2019) New insights into designing hybrid nanoparticles for lung cancer: diagnosis and treatment. J Control Release 295:250–26710.1016/j.jconrel.2019.01.009 ↗
82. Guo S et al (2019) Synergistic combination therapy of lung cancer: Cetuximab functionalized nanostructured lipid carriers for the co-delivery of paclitaxel and 5- Demethylnobiletin. Biomed Pharmacother 118:10922510.1016/j.biopha.2019.109225 ↗
83. Li K et al (2020) Dual loading of nanoparticles with doxorubicin and icotinib for the synergistic suppression of non-small cell lung cancer. Int J Med Sci 17(3):39010.7150/ijms.39172 ↗
84. Yu HA et al (2013) Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19(8):2240–224710.1158/1078-0432.CCR-12-2246 ↗
85. Wang C et al (2019) The impact of afatinib on survival in advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. J Cancer 10(4):88510.7150/jca.27528 ↗
86. Yang Y et al (2019) PLGA porous microspheres dry powders for codelivery of afatinib- loaded solid lipid nanoparticles and paclitaxel: novel therapy for EGFR tyrosine kinase inhibitors resistant nonsmall cell lung cancer. Adv Healthcare Mater 8(23):190096510.1002/adhm.201900965 ↗
87. Xie M, Xu X, Fan Y (2021) KRAS-mutant non-small cell lung cancer: an emerging promisingly treatable subgroup. Front Oncol 11:67261210.3389/fonc.2021.672612 ↗
88. Sulthana S et al (2017) Combination therapy of NSCLC using Hsp90 inhibitor and doxorubicin carrying functional nanoceria. Mol Pharm 14(3):875–88410.1021/acs.molpharmaceut.6b01076 ↗
89. Rosell R et al (2008) Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 19(2):362–36910.1093/annonc/mdm474 ↗
90. Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer–immune set point. Nature 541(7637):321–33010.1038/nature21349 ↗
91. Binnewies M et al (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24(5):541–55010.1038/s41591-018-0014-x ↗
92. Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359(6382):1350–135510.1126/science.aar4060 ↗
93. Bagherifar R et al (2021) Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives. Journal of nanobiotechnology 19:1–1810.1186/s12951-021-00861-0 ↗
94. Dolmans DE, Fukumura D, Jain RK (2003) Photodynamic therapy for cancer. Nat Rev Cancer 3(5):380–38710.1038/nrc1071 ↗
95. Weeks JC et al (2012) Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med 367(17):1616–162510.1056/NEJMoa1204410 ↗
96. Gidwani B, Vyas A (2015) The potentials of nanotechnology-based drug delivery system for treatment of ovarian cancer. Artificial Cells, Nanomedicine, and Biotechnology 43(4):291–29710.3109/21691401.2013.853179 ↗
97. Fan W et al (2017) Nanotechnology for multimodal synergistic cancer therapy. Chem Rev 117(22):13566–1363810.1021/acs.chemrev.7b00258 ↗
98. Zarrintaj P et al (2020) Poloxamer: A versatile tri-block copolymer for biomedical applications. Acta Biomater 110:37–6710.1016/j.actbio.2020.04.028 ↗
99. Yang S-J et al (2023) Cisplatin-loaded gold nanoshells mediate chemo-photothermal therapy against primary and distal lung cancers growth. Biomed Pharmacother 158:11414610.1016/j.biopha.2022.114146 ↗
100. Zarrintaj P et al (2018) Photosensitizers in medicine: does nanotechnology make a difference? Materials Today: Proceedings 5(7):15836–15844